PEAR

Stats

Summary

Pear Therapeutics, is the parent company of Pear Therapeutics (US), Inc. Pear is the leader in developing and commercializing software-based medicines, called prescription digital therapeutics (PDTs). Pear aims to redefine care through the widespread use of clinically validated software-based therapeutics to provide better outcomes for patients, smarter engagement and tracking tools for clinicians, and cost-effective solutions for payers. Pear has the first end-to-end platform to discover, develop, and deliver PDTs to patients and a pipeline of products and product candidates across therapeutic areas, including the first three PDTs with disease treatment claims from the FDA. Pear’s product, reSET®, for the treatment of substance use disorder, was the first PDT to receive marketing authorization from the FDA to treat disease. Pear’s second product, reSET-O®, for the treatment of opioid use disorder, was the first PDT to receive Breakthrough Designation. Pear’s third product, Somryst® for the treatment of chronic insomnia, was the first PDT submitted through FDA’s traditional 510(k) pathway while simultaneously reviewed through FDA’s Software Precertification Pilot Program.

Market Cap: 6.82 Million

Primary Exchange: NASDAQ

Website: peartherapeutics.com

Shares Outstanding: 143 Million

Float: 0

Dividend: 0.0 (0.0%)

Beta: 1.6274539313928578

Sector: Professional, Scientific, and Technical Services

Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)

Ethical Flags

Longest drawdown: 35 trading days

From: 2023-02-27 To: 2023-04-18

Lowest Point: